Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Invivyd (IVVD)
NASDAQ:IVVD
Holding IVVD?
Track your performance easily
IVVD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.81 - $5.20
Previous Close$0.97
Volume269.13K
Average Volume (3M)467.72K
Market Cap
$119.44M
Enterprise Value-$27.74M
Total Cash (Recent Filing)$147.88M
Total Debt (Recent Filing)$700.00K
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Nov 14, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding119,442,635
10 Day Avg. Volume439,379
30 Day Avg. Volume467,718
Standard Deviation0.42
R-Squared0.00614
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.82
Price to Sales (P/S)52.76
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-12.25
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$11.17Price Target Upside1057.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Invivyd News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInvivyd reported positive Phase 3 long-term exploratory clinical data that demonstrated PEMGARDA provided robust protection from symptomatic COVID-19 compared to placebo in immunocompetent adults.
LeadershipThe appointment of Timothy Lee as Chief Commercial Officer, an experienced commercial leader who has led successful drug launches, is expected to support the successful launch of PEMGARDA.
Regulatory ApprovalInvivyd announced general alignment with the FDA on a repeatable, accelerated Emergency Use Authorization pathway for the prevention and treatment of symptomatic COVID-19 based on streamlined clinical programs.
Bears Say
Financial GuidanceThe withdrawal of 2024 financial guidance is disappointing due to lower-than-expected revenues and cash estimates.
Revenue ShortfallPreliminary third-quarter Pemgarda net product revenue of $9.3 million came in well short of consensus at $32 million.
Sales ImpactPEMGARDA sales were negatively impacted by confusion caused by an incorrect FDA Fact Sheet that created doubt among healthcare providers.
---
Ownership Overview
32.96% Insiders
8.22% Mutual Funds
0.11% Other Institutional Investors
52.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.81 and its highest was $5.20 in the past 12 months.
What is Invivyd’s market cap?
Currently, no data Available
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is Nov 14, 2024 which is in 4 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on Aug 14, 2024. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.373 by -$0.027.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -$0.34.
How many shares outstanding does Invivyd have?
Invivyd has 119,442,635 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.373. Following the earnings report the stock price went down -7.547%.
Which hedge fund is a major shareholder of Invivyd?
Among the largest hedge funds holding Invivyd’s share is Maverick Capital ltd. It holds Invivyd’s shares valued at 13M.
---
Invivyd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.17 (1057.51% Upside)
$11.17 (1057.51% Upside)
Blogger Sentiment
Bullish
IVVD Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 617.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.51%
12-Months-Change
Fundamentals
Return on Equity
-96.56%
Trailing 12-Months
Asset Growth
-43.77%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
---
IVVD Company Deck
---
IVVD Earnings Call
Q2 2024
0:00 / 0:00
---
IVVD Stock 12 Month Forecast
Average Price Target
$11.17
▲(1057.51% Upside)
Technical Analysis
Best Analysts Covering IVVD
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
-18.72%
reiterated a buy rating 12 days ago
Copying Maxwell Skor's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -18.72% per trade.
---